Strategic framework established strategic collaboration in neurodegenerative diseases
Arcera Life Sciences (Arcera), a global life sciences company headquartered in Abu Dhabi, and Shanghai Fosun Pharmaceutical Group Co (Fosun Pharma), an innovation-driven global pharmaceutical and healthcare group, have announced the signing of a Memorandum of Understanding (MoU) to establish a long-term strategic collaboration focused on licensing, technology development, neuroscience innovation and value creation in the global life sciences sector.
The agreement was executed by Sunil Bhilotra, Chief Investment Officer, Arcera, and Xingli Wang, Co-President, Fosun Pharm &, CEO of Innovative Medicines Division in Shanghai, China. The signing ceremony was witnessed by Qunbin Wang, Co-Chairman, Fosun International; Yuqing Chen, Chairman Fosun Pharma; Isabel Afonso, Chief Executive Officer, Arcera; and Rafael Ferrer, SVP Corporate Development of Arcera.
Pathways for innovation
Aligned with the Comprehensive Strategic Partnership between the People’s Republic of China and the UAE and Abu Dhabi’s Healthcare Life Sciences Vision 2030 objectives, this MoU creates pathways for innovation and market access in both countries
“This is our first strategic partnership that will position Abu Dhabi as the bridge between Asian innovation and global markets,” stated Isabel Afonso, Arcera.
“We look forward to working closely with Arcera, leveraging our respective strengths to accelerate the delivery of innovative therapies in the Middle East and across the globe,” commented Xingli Wang, Co-President of Fosun Pharma, CEO, Innovative Medicines Division.
